+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The promise of antiangiogenic therapy for ovarian cancer



The promise of antiangiogenic therapy for ovarian cancer



Cancer Biology & Therapy 8(23): 2271-2272




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063863398

Download citation: RISBibTeXText

DOI: 10.4161/cbt.8.23.10414


Related references

The promise of antiangiogenic therapy for ovarian cancer. Cancer Biology and Therapy 8(23): 2273-2274, 2009

Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Critical Reviews in Oncology/Hematology 84(2): 224-242, 2012

Antiangiogenic therapy: preclinical premise and promise: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 810 November 1999. Molecular Medicine Today 6(5): 188-189, 2000

Antiangiogenic Therapy and Ovarian Cancer. Current Women's Health Reviews 4(1): 33-44, 2008

Antiangiogenic therapy for ovarian cancer. Current Opinion in Oncology 19(5): 497-505, 2007

Ovarian cancer and antiangiogenic therapy: caveat emptor. Journal of Clinical Oncology 32(30): 3353-3356, 2014

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American Journal of Obstetrics and Gynecology 198(4): 477.E1-9; Discussion 477.E9-10, 2008

Combination Cytotoxic and Antiangiogenic Therapy in the Management of Epithelial Ovarian Cancer. Combination Products in Therapy 1(1): 4-0, 2011

The evasive promise of antiangiogenic therapy. Journal of Hepatology 51(5): 970-972, 2009

Antiangiogenic therapy: more promise and, yet again, more questions. Journal of Clinical Oncology 21(21): 3897-3899, 2003

Immune therapy for ovarian cancer: promise and pitfalls. International Reviews of Immunology 30(2-3): 102-119, 2011

Epigenetic therapy for ovarian cancer: promise and progress. Clinical Epigenetics 11(1): 7, 2019

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of Translational Medicine 7: 49, 2009

Dose-dense therapy shows promise in ovarian cancer. Lancet. Oncology 5(12): 705, 2004

The promise and perils of 'targeted therapy' of advanced ovarian cancer. Oncology 74(1-2): 1-6, 2008